Lyra Therapeutics Faces Nasdaq Delisting Warning
Ticker: LYRA · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $2.5 million, $1.6 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: LYRA
TL;DR
Lyra Therapeutics got a Nasdaq delisting warning, needs to boost stock price in 180 days.
AI Summary
Lyra Therapeutics, Inc. announced on August 20, 2025, that it received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement for continued listing. The company has 180 calendar days to regain compliance.
Why It Matters
This filing indicates Lyra Therapeutics may be delisted from Nasdaq if it cannot meet the minimum bid price requirement, potentially impacting its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — Receiving a delisting warning from a major exchange like Nasdaq signifies significant financial distress and poses a substantial risk to the company's continued public trading.
Key Numbers
- 180 — Compliance Period (Days the company has to regain compliance with Nasdaq's minimum bid price rule.)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- Nasdaq (company) — Stock Exchange
- August 20, 2025 (date) — Date of earliest event reported
FAQ
What specific Nasdaq listing rule did Lyra Therapeutics fail to meet?
Lyra Therapeutics failed to meet the minimum bid price requirement for continued listing on Nasdaq.
What is the deadline for Lyra Therapeutics to regain compliance?
The company has 180 calendar days from August 20, 2025, to regain compliance.
What is the company's primary business?
Lyra Therapeutics, Inc. is in the business of Surgical & Medical Instruments & Apparatus (SIC code 3841).
Where is Lyra Therapeutics, Inc. incorporated?
The company is incorporated in Delaware.
What was Lyra Therapeutics previously known as?
Lyra Therapeutics, Inc. was formerly known as 480 Biomedical, Inc., Arsenal Vascular, Inc., and Arsenal Medical, Inc.
Filing Stats: 1,175 words · 5 min read · ~4 pages · Grade level 14.6 · Accepted 2025-08-22 16:15:15
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
- $2.5 million — pany's stockholders' equity be at least $2.5 million. As reported on its Form 10-Q, the Comp
- $1.6 million — y as of June 30, 2025 was approximately $1.6 million. The Deficiency Letter has no immediate
Filing Documents
- d931635d8k.htm (8-K) — 28KB
- 0001193125-25-186437.txt ( ) — 141KB
- lyra-20250820.xsd (EX-101.SCH) — 3KB
- lyra-20250820_lab.xml (EX-101.LAB) — 18KB
- lyra-20250820_pre.xml (EX-101.PRE) — 11KB
- d931635d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the submission of a plan to regain compliance, potential receipt of an extension to regain compliance, ability of the Company to comply with other Nasdaq requirements, potential delisting of the Company's common stock from the Nasdaq Capital Market, and the ability of the Company to regain compliance with Nasdaq Listing Rule 5550(b)(1). These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "would" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words or expressions. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each of which is available on the Company's Investor Relations website at investors.lyratherapeutics.com and on the SEC website at www.sec.gov. Bec
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: August 22, 2025 By: /s/ Jason Cavalier Jason Cavalier, Chief Financial Officer